前沿生物-U
(688221)
| 流通市值：36.33亿 | | | 总市值：36.33亿 |
| 流通股本：3.75亿 | | | 总股本：3.75亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 91,643,894.39 | 51,056,036.51 | 24,648,130 | 114,249,557.31 |
| 营业收入 | 91,643,894.39 | 51,056,036.51 | 24,648,130 | 114,249,557.31 |
| 二、营业总成本 | 282,018,728.06 | 185,196,329.54 | 86,698,546.2 | 465,674,966.17 |
| 营业成本 | 60,953,794.67 | 35,377,390.3 | 16,985,178.91 | 81,122,333.15 |
| 税金及附加 | 3,633,349.39 | 2,319,054.67 | 1,003,096.79 | 3,169,290.46 |
| 销售费用 | 47,921,544.66 | 34,124,281.19 | 16,798,046.4 | 64,772,461.14 |
| 管理费用 | 52,388,599.62 | 36,453,249.64 | 17,756,760.82 | 94,748,036.75 |
| 研发费用 | 109,341,964.29 | 72,701,164.58 | 34,071,674.17 | 214,231,508.17 |
| 财务费用 | 7,779,475.43 | 4,221,189.16 | 83,789.11 | 7,631,336.5 |
| 其中:利息费用 | 7,916,503.87 | 5,151,960.74 | 2,065,514.02 | 8,292,486.86 |
| 其中:利息收入 | 1,801,887.66 | 969,740.01 | 1,147,751.5 | 5,794,723.42 |
| 加:公允价值变动收益 | 991,376.04 | 849,425.97 | 1,201,780.68 | -1,055,024.89 |
| 加:投资收益 | 11,638,399.52 | 8,015,258.96 | 3,361,525.21 | 17,717,468.09 |
| 资产处置收益 | 18,798.64 | 18,798.64 | -540.77 | -3,075,667.72 |
| 资产减值损失(新) | -41,141,862.41 | -41,556,725.57 | -500,562.98 | -3,225,446.06 |
| 信用减值损失(新) | -1,470,354.38 | -77,112.91 | -137,917.62 | 54,836.01 |
| 其他收益 | 27,143,391.83 | 6,681,337.78 | 2,590,503.73 | 13,276,803.75 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -193,195,084.43 | -160,209,310.16 | -55,535,627.95 | -327,732,439.68 |
| 加:营业外收入 | 20,499.13 | 4,150.44 | 1,106.19 | 83,602.65 |
| 减:营业外支出 | 283,168.87 | 253,918.43 | 171,656.22 | 1,315,507.06 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -193,457,754.17 | -160,459,078.15 | -55,706,177.98 | -328,964,344.09 |
| 六、净利润 | -193,457,754.17 | -160,459,078.15 | -55,706,177.98 | -328,964,344.09 |
| 持续经营净利润 | -193,457,754.17 | -160,459,078.15 | -55,706,177.98 | -328,964,344.09 |
| 归属于母公司股东的净利润 | -193,457,754.17 | -160,459,078.15 | -55,706,177.98 | -328,964,344.09 |
| (一)基本每股收益 | -0.52 | -0.43 | -0.15 | -0.88 |
| (二)稀释每股收益 | -0.52 | -0.43 | -0.15 | -0.88 |
| 八、其他综合收益 | -9,917.82 | 4,068 | 213.72 | -18,571.48 |
| 归属于母公司股东的其他综合收益 | -9,917.82 | 4,068 | 213.72 | -18,571.48 |
| 九、综合收益总额 | -193,467,671.99 | -160,455,010.15 | -55,705,964.26 | -328,982,915.57 |
| 归属于母公司股东的综合收益总额 | -193,467,671.99 | -160,455,010.15 | -55,705,964.26 | -328,982,915.57 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-26 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |